Wengang Ge

519 total citations · 1 hit paper
7 papers, 252 citations indexed

About

Wengang Ge is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, Wengang Ge has authored 7 papers receiving a total of 252 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Oncology and 2 papers in Surgery. Recurrent topics in Wengang Ge's work include CRISPR and Genetic Engineering (3 papers), CAR-T cell therapy research (3 papers) and Organ Transplantation Techniques and Outcomes (2 papers). Wengang Ge is often cited by papers focused on CRISPR and Genetic Engineering (3 papers), CAR-T cell therapy research (3 papers) and Organ Transplantation Techniques and Outcomes (2 papers). Wengang Ge collaborates with scholars based in China and United States. Wengang Ge's co-authors include Yi Li, Hao Wang, Xingwang Zhang, He Huang, Mingming Zhang, Jiangtao Ren, Yongxian Hu, Yali Zhou, Li Yang and Guoqing Wei and has published in prestigious journals such as Blood, Clinical Cancer Research and Gene Therapy.

In The Last Decade

Wengang Ge

6 papers receiving 246 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

2021 202 citations Yongxian Hu, Yali Zhou et al. Clinical Cancer Research profile →

Peers

Wengang Ge

ONCOL

MB

GENET

BE

IMMUN

Roseanna M. Petrovic United Kingdom

Purva Rathi United States

Nancy P. Kren United States

Diana Gumber United States

Earle O. Assanah United States

John Pineda United States

Jiang Lv China

Robert Moot United States

Lemei Jia China

Roseanna M. Petrovic United Kingdom

Wengang Ge

238 ×1.2

ONCOL

76 ×0.7

MB

65 ×0.8

GENET

86 ×1.4

BE

104 ×2.0

IMMUN

Citations per year, relative to Wengang Ge Wengang Ge (= 1×) peers Roseanna M. Petrovic

Countries citing papers authored by Wengang Ge

Since Specialization

Citations

This map shows the geographic impact of Wengang Ge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wengang Ge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wengang Ge more than expected).

Fields of papers citing papers by Wengang Ge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wengang Ge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wengang Ge. The network helps show where Wengang Ge may publish in the future.

Co-authorship network of co-authors of Wengang Ge

This figure shows the co-authorship network connecting the top 25 collaborators of Wengang Ge. A scholar is included among the top collaborators of Wengang Ge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wengang Ge. Wengang Ge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Zhang, Xian, Junfang Yang, Jingjing Li, et al.. (2022). A Novel Universal CD7-Targeted CAR-T Cell Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma. Blood. 140(Supplement 1). 4566–4567. 12 indexed citations

2.

Hu, Yongxian, Yali Zhou, Mingming Zhang, et al.. (2021). CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. Clinical Cancer Research. 27(10). 2764–2772. 202 indexed citations breakdown →

3.

Hu, Yongxian, Yali Zhou, Mingming Zhang, et al.. (2020). The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. Blood. 136(Supplement 1). 52–52. 13 indexed citations

4.

Yin, Jie, Guoqiang Li, Yue Yu, et al.. (2008). [Mechanism of enhancement of the CTL activity in mice co-expressing CD80, CD86 and CD137L genes].. PubMed. 30(9). 654–8.

5.

Wang, Xuehao, Lünan Yan, Feng Zhang, et al.. (2006). Early experiences on living donor liver transplantation in China: multicenter report. Chinese Medical Journal. 119(12). 1003–1009. 14 indexed citations

6.

Si, Shihui, et al.. (2006). Gene therapy by membrane-expressed superantigen for α-fetoprotein-producing hepatocellular carcinoma. Gene Therapy. 13(22). 1603–1610. 10 indexed citations

7.

Wang, Xuehao, Feng Zhang, Xiangcheng Li, et al.. (2006). [Surgical methods in living donor liver transplantation: with report of 50 cases].. PubMed. 44(21). 1448–52. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact